Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis

NCT06100744 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06100744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06100744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
July 8, 2024
Completion date
October 31, 2028
Enrollment
40 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile psoriatic arthritis